Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

On August 30, 2022, the Audit Committee of the Board of Directors (the "Audit Committee") of Brickell Biotech, Inc. (the "Company") after discussion with management concluded that the interim financial statements contained in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 (the "Form 10-Q") should no longer be relied upon for the reason summarized below.

The Company is restating such interim financial statements to correct common stock share, per-share amounts, and other related balances and computations as of June 30, 2022 and December 31, 2021 and for the three- and six- month periods ended June 30, 2022 and 2021 (the "Affected Period"), to adjust them retroactively for the 1-for-45 reverse stock split implemented by the Company effective on July 5, 2022. The common stock share, per-share amounts, and other related balances and computations included in the Form 10-Q for the Affected Period did not give effect to the reverse stock split that occurred after the close of the Affected Period but before the filing of the Form 10-Q on August 12, 2022, as required. Accordingly, the Company is amending the Form 10-Q to restate the interim financial statements for the Affected Period.

The Audit Committee and Company management have discussed the matters disclosed on this Current Report on Form 8-K with the Company's independent registered public accounting firm, Ernst & Young LLP.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses